The ureido-glutatamate-based derivatives (DUPA and ACUPA) are currently the most widespread PSMA-targeting ligands employed in PCa imaging and therapeutic applications (Figure 2) [24]. The gene discussed is FOLH1; the disease is posterior cortical atrophy.